Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Peter A. van Dam(University of Antwerp), Hannelore Denys(Ghent University Hospital), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Pietro De Placido(University of Naples Federico II), Nadia Harbeck(Breast Center), Ida Paris(Agostino Gemelli University Polyclinic), Giorgio Mustacchi(University of Trieste), Grazia Arpino(University of Naples Federico II), Diana Lüftner(Beiersdorf (Germany)), Sergio Venturini(University of Turin), Rupert Bartsch(Universitätszahnklinik Wien), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Khalil Zaman, Concetta Elisa Onesti, Javier Cortés(Villa Maria Hospital), Hans Wildiers(KU Leuven), Vivianne C. G. Tjan‐Heijnen(Maastricht University Medical Centre), Mario Giuliano(Regione Campania), Mario Campone(Institut de Cancérologie de l'Ouest), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Joseph Gligorov(Sorbonne Université), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Matteo Lambertini(Ospedale Policlinico San Martino), Aleix Prat(Hospital Clínic de Barcelona), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Miguel Martín(Hospital General Universitario Gregorio Marañón), Giuseppe Curigliano(European Institute of Oncology)
Cited by 35
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k